2. Others
  3. Biochemical Assay Reagents
  4. STC314

STC314 is a histone-neutralizing agent. STC314 inhibits histone-mediated cytotoxicity, blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes. STC314 reduces histone-mediated tissue damage, thrombocytopenia, anemia, and cell death, and improves survival in preclinical models. STC314 can be used for the research of sepsis, ischemia-reperfusion injury, and deep-vein thrombosis.

For research use only. We do not sell to patients.

STC314

STC314 Chemical Structure

CAS No. : 401513-39-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

STC314 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

STC314 is a histone-neutralizing agent. STC314 inhibits histone-mediated cytotoxicity, blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes. STC314 reduces histone-mediated tissue damage, thrombocytopenia, anemia, and cell death, and improves survival in preclinical models. STC314 can be used for the research of sepsis, ischemia-reperfusion injury, and deep-vein thrombosis[1].

In Vitro

STC314 (Compound mCBS) (20-100 μg/mL; 1 h) potently inhibits histone-mediated cytotoxicity in HMEC-1 cells[1].
STC314 (12.5-400 μg/mL; 15 min-1 h) blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes[1].
STC314 (mCBS) (0.9-500 μg/mL) stabilizes human NETs and does not displace histones from chicken RBC chromatin[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

STC314 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: human microvascular endothelial cell-1 (HMEC-1)
Concentration: 0-100 μg/mL
Incubation Time: 1 h
Result: Inhibited histone-mediated HMEC-1 cytotoxicity.
In Vivo

STC314 (6.25-100 mg/kg; i.p.; single dose 10 minutes pre-histone injection) dose-dependently prevents histone-induced multi-organ damage, thrombocytopenia, and anemia in female BALB/c mice[1].
STC314 (100 mg/kg; i.p.; single dose 2 hours post-histone injection) significantly reduces ongoing histone-induced multi-organ damage and cell death in male C57BL/6 mice when administered 2 hours after histone exposure[1].
STC314 (50 mg/kg; i.p.; four total doses: 5 minutes pre-clamp, 5 minutes post-clamp removal, 24 hours post-surgery, 48 hours post-surgery) significantly improves skin flap viability in male Wistar rats following ischemia-reperfusion injury[1].
STC314 (50 mg/kg; i.v.; single dose 5 minutes post-histone injection) almost completely prevents histone-induced deep vein thrombosis in male C57BL/6 mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 5-6 weeks of age, histone-induced sepsis-like syndrome model)[1]
Dosage: 6.25 mg/kg; 25 mg/kg; 100 mg/kg
Administration: i.p.; single dose 10 minutes pre-histone injection
Result: Prevented histone-induced thrombocytopenia (maintained circulating platelet counts near control levels).
Prevented histone-induced anemia (maintained circulating red blood cell counts near control levels and reduced splenic hemoglobin accumulation to near control levels).
Reduced circulating alanine aminotransferase, lactate dehydrogenase, and creatinine levels in a dose-dependent manner, with 100 mg/kg providing the greatest reduction.
Animal Model: Wistar (male, 8-12 weeks old, 250-350 g, CLP-induced sepsis model)[2]
Dosage: 50 mg/kg
Administration: i.p.; four total doses: 5 minutes pre-CLP, 5, 10, 15 hours post-CLP
Result: Resulted in 100% survival of rats at 20 hours post-CLP (compared to reduced survival in untreated controls).
Normalized circulating alanine aminotransferase and creatinine levels, preventing CLP-induced liver and kidney damage.
Animal Model: Wistar (male, 8-12 weeks old, 250-350 g, skin flap ischemia-reperfusion injury model)[1]
Dosage: 50 mg/kg
Administration: i.p.; four total doses: 5 minutes pre-clamp, 5 minutes post-clamp removal, 24 hours post-surgery, 48 hours post-surgery
Result: Significantly increased the viable area of the ischemic skin flap, with consistent improvement observed across treated rats.
Animal Model: C57BL/6 (male, 8 weeks of age, histone-induced deep vein thrombosis model)[1]
Dosage: 50 mg/kg
Administration: i.v.; single dose 5 minutes post-histone injection
Result: Almost completely inhibited histone-induced DVT, with thrombus weights reduced to near sham-operated control levels.
Clinical Trial
Molecular Weight

1070.64

Formula

C13H17Na7O32S7
CAS No.
SMILES

O=[S](O[C@H]([C@H]1O[S](=O)(O[Na])=O)[C@@H]([C@H](O[C@H]1OC)CO[S](=O)(O[Na])=O)O[C@H](O[C@@H]2CO[S](=O)(O[Na])=O)[C@@H]([C@H]([C@@H]2O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)(O[Na])=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

STC314 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

STC314401513-39-1STC 314STC-314Biochemical Assay Reagentshuman plateletsphagocytesneutrophil extracellular trapHMEC-1 cellsC57BL/6 miceBALB/c miceextracellular histonesWistar ratsDNase1human erythrocytesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
STC314
Cat. No.:
HY-145996
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.